Real, Jordi
Vlacho, Bogdan
Ortega, Emilio
Vallés, Joan Antoni
Mata-Cases, Manel
Castelblanco, Esmeralda
Wittbrodt, Eric T.
Fenici, Peter
Kosiborod, Mikhail
Mauricio, Dídac
Franch-Nadal, Josep http://orcid.org/0000-0002-5175-1555
Funding for this research was provided by:
AstraZeneca Spain (4R17/071-3)
Article History
Received: 10 March 2021
Accepted: 23 June 2021
First Online: 9 July 2021
Declarations
:
: The study was approved by the Ethics Committee of the Primary Health Care University Research Institute (IDIAP) Jordi Gol following the Spanish regulations on observational studies (Approval Number: P17/153).
: Not applicable.
: The CVD REAL study was conceived and funded by AstraZeneca, and led by its independent Executive Scientific Board. The CVD REAL Catalonia study design adaptation, data collection and analyses have been conducted independently from AstraZeneca. The manuscript writing, results interpretation and conclusions are those of the authors alone. M. M.-C. has received advisory honorarium from Astra-Zeneca, Bayer, Boehringer Ingelheim, GSK, Lilly, MSD, Novartis, Novo Nordisk, and Sanofi; he has received speaker honorarium from Astra-Zeneca, Bayer, Boehringer Ingelheim, GSK, Lilly, Menarini, MSD, Novartis, Novo Nordisk, and Sanofi; he has received research grants to the institution from Astra-Zeneca, GSK, Lilly, MSD, Novartis, Novo Nordisk, and Sanofi. J. F.-N. has received advisory and or speaking fees from Astra-Zeneca, Ascensia, Boehringer Ingelheim, GSK, Lilly, MSD, Novartis, Novo Nordisk, and Sanofi; he has received research grants to the institution from Astra-Zeneca, GSK, Lilly, MSD, Novartis, Novo Nordisk, Sanofi, and Boehringer. D. M. has received advisory and/or speaking fees from Astra-Zeneca. Ascensia, Boehringer Ingelheim, GSK, Lilly, MSD, Novartis, Novo Nordisk, and Sanofi; he has received research grants to the institution from Astra-Zeneca, GSK, Lilly, MSD, Novartis, Novo Nordisk, Sanofi, and Boehringer. M. K. reports research grants fees from Astra Zeneca, Boehringer Ingelheim; consultant/Advisory Board fees from Amgen, Applied Therapeutics, Astra Zeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen, Merck (Diabetes), Novo Nordisk, Sanofi and Vifor Pharma; other research support fees from Astra Zeneca, and Honorarium fees from Astra Zeneca, Boehringer Ingelheim, Novo Nordisk. P. F. and E. T. W. are full time employees of AstraZeneca. P. F., M. K. and E. T. W. are members of the CVD REAL Executive Scientific Committee, conceived and led the initial CVD REAL global studies and analyses. J. R. B. V. and E. C. have no conflict of interest to declare.